The American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Meeting occurred Nov. 12-16, 2026. Allergists and immunologists from around the world came together with students, residents, fellows, allied health professionals, and other medical specialists to expand knowledge within the theme of “building for our future.” There were numerous booths that supported the use of biologics in treating allergic disease, with patient-specific outcomes highlighted in abstracts and case reports.
A ubiquitous biologic in allergy today, dupilumab is a monoclonal antibody initially FDA-approved to treat moderate-to-severe atopic dermatitis, with expanded approval for conditions including asthma, chronic spontaneous urticaria, eosinophilic esophagitis (EoE), and more. Dupilumab binds to the IL-4Rα receptor, preventing signaling of cytokines IL-4 and IL-13, which together drive type two inflammatory pathways. Several abstracts at the annual meeting discussed dupilimab's rare unintended consequences, with notable examples including psoriasis, lichen planus, juvenile dermatomyositis, and alopecia areata.
Our abstract presented at the ACAAI meeting was titled “Enterobiasis Associated with Dupilumab Treatment for Eosinophilic Esophagitis.” In this report, we discussed a fascinating case of a pediatric patient being treated with dupilumab for EoE. The patient had been receiving dupilumab for over two years with adequate EoE control before presenting to the emergency department with headache and vision loss. The absolute eosinophil count (AEC) was remarkably elevated at 17,200 cells/uL, prompting admission and multidisciplinary diagnostic evaluation. Notably, family history was positive for maternal hypereosinophilic syndrome of unknown etiology. Testing included brain CT/MRI, orbital ultrasound, lumbar puncture, stool studies, and bone marrow biopsy, all of which were unrevealing. Flexible sigmoidoscopy found extensive Enterobius vermicularis worms. Once malignancy had been ruled out, the patient was treated with a five-day course of prednisone as well as two doses of albendazole, separated by two weeks. Headache and vision changes rapidly improved, with the eosinophil count normalizing within two weeks of hospitalization. Dupilumab was held. Upon discovery of persistence of pinworms, a 16-week albendazole taper along with treatment of household members was initiated. The patient is now asymptomatic, with no recurrence of pinworms or eosinophilia. They were initially lost to follow-up after hospitalization but are currently on oral budesonide, awaiting a multidisciplinary EoE clinic visit next month.
This unique case highlights a rare potential risk for patients on dupilumab: significant hypereosinophilia in the setting of parasitic infection. It is known that dupilumab may cause a transient hypereosinophilia, typically within six months of starting treatment, with AECs averaging from 400-700 cells/uL. It is also known that mild eosinophilia can occur with pinworm infection. Hypereosinophilia to our patient’s degree should prompt a more extensive evaluation, with the knowledge that stool studies may be unrevealing.
Dupilumab and other targeted monoclonal antibodies have expanded our ability to provide targeted therapies that are usually quite effective. Our case, and others at the ACAAI annual meeting, demonstrate the need for physicians to remain vigilant to rare adverse effects as we continue to “build our future” within the realm of allergic disease.



